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lung carcinomas are found in 0.8%-8% [7] [8] [9] [10] [11] [12] [13] and have some distinct histomorphological features [8, 11, 14, 15] . V600E represents over 50% of BRAF mutations in lung carcinoma, whereas fewer mutations are found at the G469A and G594G sites [8] [9] [10] . PLX4032 is the first BRAF-specific inhibitor to show promising clinical activity in melanoma patients [16] . Interestingly, a lung adenocarcinoma case with BRAF-V600E mutation showed a response to this drug [17] .
Ethnic-specific differences in the frequency of BRAF mutations have also been reported in various cancers, as with EGFR mutations in nonsmall-cell lung carcinoma (NSCLC). The frequency of BRAF mutations in colorectal cancer is markedly higher in patients of Anglo-Saxon descent than in those of southern European descent [18] , whereas the frequency of BRAF mutations in prostate cancer is higher in Asians than in Americans [3] . However, there have been few reports [7, 12] on the prevalence of BRAF mutations in lung carcinoma patients of Asian ethnicity.
In this article, we determined BRAF mutation status and its correlation with clinicopathological features in large number of Asian populations, by high-resolution melting analysis (HRMA) followed by Sanger sequencing and/or deep sequencing using next generation sequencer.
materials and methods case selection
This study was approved by the institutional review board of the National Cancer Center Hospital (Tokyo, Japan). Specimens were obtained from 2043 patients who underwent surgical resection for primary lung cancer at the National Cancer Center Hospital between 1993 and 2009. Forty-two patients who received neoadjuvant chemotherapy were excluded. Histological diagnosis was based on the latest edition of the World Health Organization classification of lung tumors [19] .
analysis of BRAF, EGFR, KRAS mutation status, and ALK rearrangement Molecular-based mutation status was analyzed in fresh frozen (in liquid nitrogen; 989 of 2001 [49.4%]) and formalin or methanol-fixed, paraffin-embedded (1012 of 2001 [50.6%]) tissues of surgically resected lung cancer specimens. Methods of mutation detection by HRMA followed by verification by Sanger sequencing or deep sequencing using a high-speed sequencer are summarized in supplementary Tables S1 and S2 and Note available at Annals of Oncology online.
Echinoderm microtubule-associated protein-like 4 gene and ALK fusions were analyzed by immunohistochemistry, reverse transcriptase (RT)-PCR, and/or fluorescence in situ hybridization assay [20] .
immunohistochemistry For immunohistochemical staining, 4-µm-thick sections of the paraffinized tumor samples were routinely deparaffinized. Detailed antigen retrieval methods and antibody dilution for each primary antibody are listed in supplementary Table S3 , available at Annals of Oncology online.
All sections were stained with hematoxylin and eosin for morphological analysis by an automated strainer. Only BRAF-mutated tumors were stained with Alcian blue-periodic acid-Schiff (AB-PAS) for detection of mucin-containing tumor cells.
statistical analysis
Statistical analysis was carried out using the SPSS Statistics 21 program (IBM Corporation, Somers, NY). Survival curves were calculated by the Kaplan-Meier method. A P value of <0.05 was considered statistically significant.
results patient characteristics
A total of 2001 patients with surgically resected NSCLC were included in the present analysis (supplementary Table S4 , available at Annals of Oncology online). All patients were Asian. The NSCLC cases consisted of 1835 adenocarcinomas, 160 squamous cell carcinomas, 5 large cell neuroendocrine carcinomas, and 1 adenosquamous carcinoma. The median follow-up time was 61 months after surgical treatment. Among the 1835 adenocarcinomas, the most common histological subtype was papillary predominant (34.8%), followed by lepidic predominant (19.7%), solid predominant (12.7%), acinar predominant (9.3%), minimally invasive adenocarcinoma (MIA; 8.5%), micropapillary predominant (6.3%), and adenocarcinoma in situ (AIS; 4.7%). Other invasive types of adenocarcinoma included invasive mucinous adenocarcinoma (IMA; 3.9%) and colloid adenocarcinoma (0.05%).
BRAF mutations
Of the 2001 surgically resected NSCLC cases, the first HRMA screening detected 33 cases (1.6%) with abnormal BRAF band patterns compared with wild-type BRAF. The presence of BRAF mutations was verified by sequencing of PCR products in 26 (78.8%) of the 33 suspicious BRAF mutation cases, whereas mutations were not found in the remaining 7 cases (21.2%). Four cases with BRAF-mutated tumor were detected by Sanger sequencing and 24 cases with BRAF mutated tumor were detected by deep sequencing, respectively (supplementary Figures S1 and S2, available at Annals of Oncology online). We confirmed that two cases with BRAF-mutated tumor were detected by both Sanger sequencing and deep sequencing. On the other hand, seven cases with suspicious BRAF mutation were not detected by deep sequencing (supplementary Table S5 , available at Annals of Oncology online); therefore, they were judged as being negative. Thirteen kinds of mutation genotypes were identified in the 26 BRAF mutation cases (supplementary Figure S3 , available at Annals of Oncology online). V600E, G469A, and K601E were present in 8 (30.8%), 6 (23.1%), and 4 (15.4%) cases, respectively. Other residual mutations (G464E, G466R, G466V, S467L, D594N, D594G, G596R, A598T, T599_V600insT, G606R) were present in only one case each (0.04%), and two cases (V600E/G606R or G464E/G466R) had two genotypes. Four cases had genotypes (G464E, G596R, A598T, and G606R) that have not been previously reported in lung cancer. However, all the BRAF mutation types detected in the present study were already registered the Catalogue of Somatic Mutations in Cancer (COSMIC) database (supplementary Table S5 , available at Annals of Oncology online); therefore, they were believed to be oncogenic mutations. BRAF-mutated tumors were present in 13 women and 13 men with an average age of 64 years (range, 44-81 years). Fourteen patients (54%) were current or former smokers. Six tumors originated in the right upper lobe, five in the right middle lobe, six in the right lower lobe, four in the left upper lobe, two in the left lower lobe, and three in other locations. The average tumor size was 2.2 cm (range, 0.8-4.5 cm). Pathological stage varied and included IA (n = 13), IB (n = 4), IIA (n = 3), IIB (n = 1), IIIA (n = 4), and IIIB (n = 1). Regarding tumor histology, 25 tumors were adenocarcinomas and 1 tumor was squamous cell carcinoma. BRAF-mutated adenocarcinomas showed varied histomorphology. Papillary or micropapillary growth was present in 50% of BRAF-mutated adenocarcinomas ( Figure 1A and B ). In V600E-mutated cases, the predominant growth pattern was papillary in two cases, micropapillary in two cases, solid in three cases, and AIS in one case. Focal micropapillary patterns were observed in 50% of V600E-mutated cases. In non-V600Emutated cases, the predominant growth pattern was papillary in eight cases, solid in two cases, and nonmucinous AIS in three cases. Lepidic, micropapillary, MIA, and IMA were each present in one case. Because of the limited numbers available, histopathological features were not evaluated in the other genotypes. Clearcell changes were detected at least focally in the majority (75%) of V600E-positive cases ( Figure 1C and D) . Some, but not all, clear cells were positive for surfactant apoprotein A (SP-A) but negative for AB-PAS. In addition, 86% of V600E-mutated cases were positive for thyroid transcription factor-1 (TTF-1).
correlation between BRAF mutations and other driver gene alterations in NSCLC
EGFR and KRAS mutations were detected in 849 (42.4%) and 171 (8.5%) cases, respectively, by HRMA. ALK rearrangement was present in 41 (3.3%) of the 1247 investigated cases. Tumors with V600E BRAF mutations did not have concomitant mutations in EGFR or KRAS or ALK rearrangement. In contrast, five tumors with non-V600E BRAF mutations (four G469A and one G464E/G466R) showed concomitant EGFR mutations (four L858R and one DEL), and one tumor with S467L BRAF mutation showed a concomitant KRAS mutations. Overall survival ( Figure 2) was not significantly different between patients with wild-type BRAF and those with mutated BRAF (P = 0.42). In addition, overall survival was not significantly different between patients with wild-type BRAF and those with V600E or non-V600E-mutated BRAF (P = 0.49 and P = 0.15, respectively). Overall survival was not significantly different between patients with stage I and II disease who had wild-type BRAF and those who had mutated BRAF (P = 0.27 and P = 0.80, respectively). Multivariate analysis was not feasible because of the relatively small number of deaths in each BRAF mutation genotype group.
discussion
In the present study, we investigated the incidence of BRAF mutations and their association with clinicopathological features and prognosis in a predominantly Asian population with surgically resected NSCLC. We found that the incidence of BRAF mutations in NSCLC was 1.3%. Thirteen kinds of BRAF mutation genotypes were detected, and 4 of the 13 genotypes had not been previously detected in lung cancer. BRAF mutation status did not have any prognostic value in NSCLC.
Previous studies have reported that the frequency of BRAF mutations in lung adenocarcinoma in Asian populations is low (0.8%-1.1%) [7, 12] . Our incidence rate of 1.3% is consistent with these reports. These incidence rates were lower than those reported in Caucasian populations (∼3%) [8, 9, 11] . The relative paucity of BRAF mutations in the Asian population may be related to ethnic differences and the high frequency of EGFR mutations in Asian women with lung adenocarcinoma. In the present study, V600E and non-V600E mutation genotypes had an equal sex and smoking history distribution. These results are in agreement with those of previous studies [8, 9, 11] .
In lung cancer, several BRAF mutation genotypes in NSCLC have been reported. Paik et al. [9] reported the presence of three genotypes in lung adenocarcinoma, including V600E, G469A, and D594G. Marchetti et al. [8] reported the presence of 14 genotypes in NSCLC (13 adenocarcinomas and 1 squamous cell carcinoma). We also identified 13 genotypes, including the predominant V600E and G469A mutations. The frequency of V600E (30.8%) in the present study was lower than that reported in the abovementioned studies, whereas the frequency of G469A (23.1%) was similar to that of Paik et al. [9] . In addition, we detected BRAF mutations not previously reported in lung carcinoma, including G464E, G596R, A598T, and G606R. These individual mutations occur at a low frequency in a wide variety of other cancers [1, 2, 6, [8] [9] [10] 12] . Although, the lung is the most common site of metastasis in the natural history of malignant tumors, our four cases with G464E, G596R, A598T, or G606R mutation were confirmed to be of pulmonary, as evidenced by the expression of TTF-1 [21] .
Our data indicated that postoperative overall survival was similar between NSCLC patients with wild-type BRAF and those with mutated BRAF. Furthermore, patients with BRAF mutations had relatively low-stage disease. In contrast to our study, Marchetti et al. [8] reported that V600E mutations in radically resected primary lung adenocarcinoma had relatively high-stage disease and poor disease-free survival and overall survival. The small number of BRAF mutation cases in our study precluded the drawing of definitive conclusions concerning the prognostic significance of BRAF mutations in NSCLC. Further multicenter studies with larger patient populations are necessary to establish the role of BRAF mutations in NSCLC prognosis. V600E mutations have been associated with poor prognosis in patients with colorectal cancer [5] and papillary thyroid cancer [4] . In contrast, BRAF mutations did not affect the disease-free interval or overall survival in primary melanoma [22] . Together, these findings indicate that the prognostic significance of BRAF mutations is influenced by disease site.
It has been previously reported that BRAF, EGFR, and KRAS mutations are mutually exclusive events [2, 7, 9, 11, 23] . In our study, V600E BRAF mutations were present exclusively; however, five non-V600E BRAF-mutated tumors (four G469A and one G464E/G466R) exhibited concomitant EGFR mutations (four L858R and one DEL). In agreement with our observations, Marchetti et al. [8] also reported the presence of concomitant V600E BRAF and EGFR mutations (two DEL) in two lung tumors. Recently, Ohashi et al. [24] reported that lung cancer samples with acquired resistance to EGFR-TKIs occasionally harbor BRAF mutations. Of our five non-V600E BRAFmutated and EGFR-mutated NSCLC cases, only one case showed intrapulmonary metastasis after surgery but EGFR-TKIs were not effective. This finding supports a potential mechanistic role of BRAF mutations in acquired resistance to EGFR-TKIs in lung cancer. We should pursue the correlation among the clinical implications in the presence or absence of molecularly targeted agent in the future.
BRAF-mutated lung carcinomas showed varied histomorphology. According to recent reports, adenocarcinoma is the predominant histological type in BRAF-mutated lung carcinoma [7, 8, 13] , whereas squamous cell carcinoma is rare [1, 7, 8, 13] . Furthermore, V600E-positive cases have been shown to exhibit a more aggressive tumor histotype, which is characterized by micropapillary features [8, 15] and acinar and solid growth [11, 14] . Intriguingly, we detected a BRAF mutation (K601E) in one case of squamous cell carcinoma. In addition, papillary (micropapillary) predominant, solid predominant, and focal micropapillary patterns were present in 50%, 38%, and 50% of V600E-positive adenocarcinomas, respectively. Of note, clear-cell changes were identified at least focally in 75% of V600E-positive cases. The nature of these clear-cell changes was not entirely clear; however, a few clear cells were positive for SP-A and negative for mucin and adipophilin. It is possible that clear-cell changes are induced, at least partially, by excessive accumulation of surfactant proteins in the tumor cell cytoplasm. In contrast to the V600E genotype, there are few reports on the histomorphology of other BRAF mutation genotypes. Because of the small number of the other mutation genotypes in our study, histomorphological features could not Recently, indirect methods were developed to detect gene mutations, including Scorpion ARMS, the peptide nucleic acidlocked nucleic acid PCR clamp, mutant-enriched PCR, the smart amplification process, and HRMA. In the present study, 33 (1.6%) cases with abnormal BRAF band patterns were detected by HRMA, and 26 (78.8%) of these 33 cases were confirmed by sequencing of PCR products. The targets of recent developed BRAF inhibitor were V600E or V600K mutations [25] . Our results indicated that sequencing is the gold standard method for detecting specific genotypes; however, indirect methods may serve as screening tools to detect the presence of any BRAF mutation. Next-generation sequencing platforms, such as the Ion Torrent, can introduce some errors. However, BRAF mutations were detected using both the HRMA and Sanger sequencing and/or deep sequencing. All these mutations are deposited in the COSMIC database. Therefore, these BRAF mutations were considered to be oncogenic ones. To obtain precise data, high-quality DNA extracted from an adequate amount of pure tumor cells is required and this is expensive and time-consuming. A novel BRAF antibody offers promise for the immunohistochemical detection of BRAF mutations [15] and needs to be validated in V600E-mutated lung tumors.
In conclusion, BRAF mutations in lung cancer were rare in an exclusively Asian population. BRAF mutation status lacked prognostic significance in this patient population.
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